Syntaxin has named Patrick James Doyle CEO. Doyle joins Syntaxin from Metabolex, California, where he held the post of chief corporate development.
Cipher Pharmaceuticals has promoted its president, Larry Andrews, to CEO. He replaces, John Mull, who will stay on as chairman.
MGI PHARMA has named Mary Lynne Hedley, Ph.D., Eric P. Loukas, Esq., and William F. Spengler to executive vice president and appointed Loukas as COO.
BioSyntech has named Francois Michaud C.A., C.M.A., as CFO and Richard Lacombe Ph.D., M.B.A., as vice-president clinical affairs.
Neopharm named Ronald Pauli as CFO, effective Sept. 1. He replaces Lawrence Kenyon.
Celator Pharmaceuticals has named Arthur C. Louie, M.D., as chief medical officer.
Callisto Pharmaceuticals has named Robert C. Shepard, M.D., F.A.C.P. as its chief medical officer.
NSP advises that Vincenzo Guerrieri and Marc Greenberger have resigned as directors of NSP. Henry Evans had resigned as secretary of NSP and executive vice-president of Naturale Science Pharma Inc. NSPI did not renew the consulting agreement for Philip Antunes, COO, which terminated July 31, 2006.
Inspire Pharmaceuticals has hired two new vice presidents: Bart J. Dunn as vice president, business development and Raymond W. Hines as vice president, associate general counsel.
AVANIR Pharmaceuticals has hired Theresa Hope-Reese as vice president of human resources.
John Friedman has stepped down from the board of directors of Acorda Therapeutics.
Icagen has appointed Adeoye Y. Olukotun, M.D., MPH, FACC to its board of directors.
Dr. Gerald Batist, the director of the McGill Center for Translational Research in Cancer based at the Jewish General Hospital in Montreal, has joined Chemokine Therapeutics' clinical advisory board.